Search
for

    Learn

    5 / 18 results

      learn Ketoconazole

      antifungal with some anti-androgenic benefits, often used as a shampoo

      learn Procyanidin

      bioflavonoid found in plants with antioxidant and hair stimulating properties

      learn Clascoterone

      a novel topical treatment that inhibits DHT on androgen receptors

      learn Saw Palmetto

      a natural and far less effective alternative to Finasteride

    Research

    5 / 1000+ results

    Community Join

    5 / 487 results

      community Fats on your Head to Stop Hair Loss?

      in Research/Science  138 upvotes 9 months ago
      The conversation discusses the potential of long-chain unsaturated fatty acids, like oleic and linoleic acid, as an additional treatment for hair loss, which may inhibit the enzyme responsible for converting testosterone to DHT and promote hair growth. Users humorously suggest using oils topically and discuss other hair loss treatments, but the main focus is on the science behind fatty acids and their role in hair health.

      community A concise, easy-to-understand post on Androgenic Alopecia theory and its practical applications

      in Research/Science  92 upvotes 2 years ago
      The mechanism of Androgenic Alopecia and practical applications of treatments like Minoxidil, Finasteride, RU58841, dermarolling, scalp massages, anti-fungals, progesterone, estrogen, PPAR-γ activators, reducing oxidative stress, and scalp exercises. It explains why DHT is important in AA and how other factors might be involved such as hypoxia, increased DKK-1 expression, morphological changes to the scalp, skull growth during childhood/puberty, and blood flow.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  40 upvotes 1 year ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.